Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

• Results Overview

  This long-term safety study of upadacitinib across multiple inflammatory conditions showed the medication was generally well-tolerated, with different side effect patterns observed depending on the underlying condition being treated.

• Study Summary

  Num Participants:

  6,991

  Study Type:

  Observational

  Control Group:

  Adalimumab And Methotrexate (In Some Ra And Psa Studies Only)

  Efficacy End Points Treatment:

  {'TEAEs': '205.5-278.1', 'TEAEs leading to discontinuation': '4.5-5.4'}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Herpes Zoster	Medium	1.6
  Non-Melanoma Skin Cancer	High	0.8
  Serious Infections	High	3.9
  Venous Thromboembolism	High	0.4
  Malignancies	High	1.4
  Elevated Creatine Phosphokinase Levels	Medium	7.9

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected